Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33,556 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of concomitant H1 antihistamine and immune checkpoint inhibitor therapy on survival outcome and safety in patients with advanced primary lung cancer: a cohort study.
Zhang WH, Li BX, Ma CX, Wang J, Yang F, Xiong YJ, Li SZ, Zhang JL, Du WJ, Hui ZZ, Shen M, Zhou L, Li RM, Tian X, Han Y, Ren BZ, Ichiki Y, Lee SC, Zhang XW, Cao S, Ren XB, Liu L. Zhang WH, et al. Among authors: zhou l. Transl Lung Cancer Res. 2024 Oct 31;13(10):2787-2801. doi: 10.21037/tlcr-24-795. Epub 2024 Oct 28. Transl Lung Cancer Res. 2024. PMID: 39507043 Free PMC article.
A nomogram incorporating Ki67 to predict survival of acral melanoma.
Du Y, Li C, Mao L, Wei X, Bai X, Chi Z, Cui C, Sheng X, Lian B, Tang B, Wang X, Yan X, Li S, Zhou L, Guo J, Si L. Du Y, et al. Among authors: zhou l. J Cancer Res Clin Oncol. 2023 Nov;149(14):13077-13085. doi: 10.1007/s00432-023-05127-w. Epub 2023 Jul 20. J Cancer Res Clin Oncol. 2023. PMID: 37470854 Free PMC article.
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapy.
Dai J, Bai X, Gao X, Tang L, Chen Y, Sun L, Wei X, Li C, Qi Z, Kong Y, Cui C, Chi Z, Sheng X, Xu Z, Lian B, Li S, Yan X, Tang B, Zhou L, Wang X, Xia X, Guo J, Mao L, Si L. Dai J, et al. Among authors: zhou l. J Immunother Cancer. 2023 Jan;11(1):e005937. doi: 10.1136/jitc-2022-005937. J Immunother Cancer. 2023. PMID: 36593066 Free PMC article.
Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma.
Tang B, Xiao J, Chi Z, Duan R, Cui C, Si L, Liu Y, Hu X, Liu Z, Xiang P, Li S, Yan X, Zhou L, Li J, Li Y, Yu X, Dai X, Li X, Guo J, Sheng X. Tang B, et al. Among authors: zhou l. Oncologist. 2024 Oct 17:oyae260. doi: 10.1093/oncolo/oyae260. Online ahead of print. Oncologist. 2024. PMID: 39418340 Free article.
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.
Mao L, Lian B, Li C, Bai X, Zhou L, Cui C, Chi Z, Sheng X, Wang X, Tang B, Yan X, Li S, Kong Y, Dai J, Wei X, Li J, Duan R, Xu H, Wu X, Yang Y, Cheng F, Zhang C, Xia F, Pang Z, Guo J, Si L. Mao L, et al. Among authors: zhou l. JAMA Oncol. 2023 Aug 1;9(8):1099-1107. doi: 10.1001/jamaoncol.2023.1363. JAMA Oncol. 2023. PMID: 37261804 Free PMC article. Clinical Trial.
Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
Zhang X, Zhou L, Zhou C, Shen L. Zhang X, et al. Among authors: zhou c, zhou l. Adv Ther. 2024 Jun;41(6):2112-2132. doi: 10.1007/s12325-024-02838-5. Epub 2024 Apr 15. Adv Ther. 2024. PMID: 38619719 Free PMC article. Review.
33,556 results
You have reached the last available page of results. Please see the User Guide for more information.